Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Recommendation of “Hold” by Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been given an average recommendation of “Hold” by the six research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $7.25.

A number of equities analysts have issued reports on RXRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. increased its position in Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after buying an additional 2,200 shares in the last quarter. AlphaQuest LLC bought a new position in shares of Recursion Pharmaceuticals during the first quarter valued at $36,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Recursion Pharmaceuticals by 97.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after acquiring an additional 4,446 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $51,000. Finally, PFG Investments LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth about $53,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.63 on Friday. The company has a 50-day simple moving average of $5.15 and a two-hundred day simple moving average of $5.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The firm has a market capitalization of $2.41 billion, a PE ratio of -2.60 and a beta of 0.93. Recursion Pharmaceuticals has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business’s revenue for the quarter was down 80.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.34) EPS. On average, analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.